Hyperfine Inc

Hyperfine Inc(HYPR)の株式分析

$0.833

-0.012 (-1.44%)終値時点

Loading chart…
High
0.857
Open
0.852
VWAP
0.84
Vol
326.41K
Mkt Cap
68.77M
Low
0.831
Amount
274.34K
EV/EBITDA, TTM
-1.07

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

AI analysis of Hyperfine Inc (HYPR)

sell

Hyperfine Inc (HYPR) is not a good buy right now due to its current price of $0.8332, which is significantly below the analyst price target of $2. Additionally, the RSI is at a very low 19.399, indicating oversold conditions, but the overall negative momentum and insider selling of 6311.17% raise concerns. The main risk is the company's ongoing losses, with a net income of -9,298,000 USD in Q2 2026, which suggests financial instability despite some revenue growth.

バリュエーション指標

The current forward P/E ratio for Hyperfine Inc (HYPR) is 0.00, compared to its 5-year average forward P/E of -2.07.

Forward P/E

Overvalued
5Y Average P/E
-2.07
Current P/E
0.00
割高
-0.97
割安
-3.17

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.82
Current EV/EBITDA
-1.07
割高
1.00
割安
-2.64

Forward P/S

Fair
5Y Average P/S
7.53
Current P/S
3.41
割高
15.77
割安
-0.71

Whales holding HYPR

A

Alphabet Inc.

+ HoldingHYPR

-43.87%

3M Return

イベントタイムライン

2026-08-26 (ET)

08:30:00

Hyperfine Announces NEURO PMR Study Results

2026-08-20 (ET)

08:30:00

Hyperfine Receives FDA Clearance for Optive AI Software Update

2026-08-06 (ET)

16:30:00

Hyperfine Q2 Revenue at $3.904M, Below Consensus

2026-07-01 (ET)

08:30:00

Hyperfine Launches Next-Gen Swoop System in Europe

2026-06-22 (ET)

08:30:00

Hyperfine Forms Neurosurgery Advisory Council

ニュース

HYPR FAQ — answered by Alphio AI

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Hyperfine Inc (HYPR) is not a good buy right now due to its current price of $0.8332, which is significantly below the analyst price target of $2. Additionally, the RSI is at a very low 19.399, indicating oversold conditions, but the overall negative momentum and insider selling of 6311.17% raise concerns. The main risk is the company's ongoing losses, with a net income of -9,298,000 USD in Q2 2026, which suggests financial instability despite some revenue growth.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める